| 1 |
Unterrainer M, Niyazi M, Tonn JC, Ilhan H, Bartenstein P, Albert NL. A look ahead: future directions of SSR-directed imaging and therapy in meningioma. Clin Transl Imaging 2019;7:357-62. [DOI: 10.1007/s40336-019-00333-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 2 |
Jin X, Auernhammer CJ, Ilhan H, Lindner S, Nölting S, Maurer J, Spöttl G, Orth M. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. J Nucl Med 2019;60:1240-6. [DOI: 10.2967/jnumed.118.224048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 3 |
Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
|
| 4 |
Cives M, Pelle’ E, Quaresmini D, Mandriani B, Tucci M, Silvestris F. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Curr Treat Options in Oncol 2019;20. [DOI: 10.1007/s11864-019-0669-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 5 |
Adant S, Shah GM, Beauregard J. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2020;47:907-21. [DOI: 10.1007/s00259-019-04499-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 6 |
Telo S, Filice A, Versari A, Lamberti G, Campana D, Calabrò D, Fanti S, Ambrosini V. Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. Clin Transl Imaging 2021;9:423-38. [DOI: 10.1007/s40336-021-00443-y] [Reference Citation Analysis]
|
| 7 |
Shah RG, Merlin MA, Adant S, Zine-Eddine F, Beauregard JM, Shah GM. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers (Basel) 2021;13:E232. [PMID: 33435224 DOI: 10.3390/cancers13020232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Ebbers SC, Heimgartner M, Barentsz MW, van Leeuwaarde RS, van Treijen MJC, Lam MMEG, Braat AJAT. Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. Eur J Hybrid Imaging 2021;5:22. [PMID: 34881405 DOI: 10.1186/s41824-021-00116-z] [Reference Citation Analysis]
|
| 9 |
Thakral P, Sen I, Das SS, Manda D, Cb V, Malik D. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br J Radiol 2021;:20210403. [PMID: 34357794 DOI: 10.1259/bjr.20210403] [Reference Citation Analysis]
|
| 10 |
Malcolm J, Falzone N, Lee BQ, Vallis KA. Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. Cancers (Basel) 2019;11:E268. [PMID: 30823564 DOI: 10.3390/cancers11020268] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 11 |
Özdirik B, Amthauer H, Schatka I, Goretzki PE, Mogl MT, Fehrenbach U, Tacke F, Jann H, Roderburg C. A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. Mol Clin Oncol 2021;14:20. [PMID: 33363730 DOI: 10.3892/mco.2020.2182] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, Sathekge M. The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nucl Med Mol Imaging 2021;55:136-40. [PMID: 34093893 DOI: 10.1007/s13139-021-00696-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
